Výsledky vyhledávání

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma

Autor: Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman

Publikováno v: Blood Advances. 7:1488-1495

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc1b97a21d171847f261eab8a339b3c
https://doi.org/10.1182/bloodadvances.2022008344

Zobrazit plný text záznamu

Flow cytometric monocyte repartition demonstrates overlap between chronic myelomonocytic leukaemia and myeloid neoplasms with monocytosis

Autor: Sharon A, Allen, Eugene, Ng, Uwe H, Hahn, Tatjana, Banovic, David M, Ross

Publikováno v: Pathology. 54:953-955

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1155e0447ea4850aed7f3d9c8ba099a6
https://doi.org/10.1016/j.pathol.2021.12.294

Zobrazit plný text záznamu

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Publikováno v: Blood. 140:9399-9401

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1f7868cb8f4753a14dce1329b53f2d5
https://doi.org/10.1182/blood-2022-156576

Zobrazit plný text záznamu

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Autor: Anas Younes, John M Burke, Bruce D. Cheson, Catherine Diefenbach, Silvia Ferrari, Uwe H Hahn, Eliza A Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, Aparna Raval, Mahesh R. Shivhare, Tina G Nielsen, Gila Sellam, Jeff P. Sharman

Publikováno v: Blood. 134:2874-2874

Introduction: Up to 40% of patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) fail to achieve remission, or relapse, with standard-of-care rituximab (R) plus CHOP (R-CHOP). Atezolizumab (atezo) is a fully humanized anti-pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ee426441da1652f229370c878a2b53f
https://doi.org/10.1182/blood-2019-123368

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání